RenovoRx, Inc. (RNXT)
1.67
+0.19
(+12.84%)
USD |
NASDAQ |
Aug 28, 16:00
1.70
+0.03
(+1.80%)
After-Hours: 20:00
RenovoRx Debt to Equity Ratio : 0.0434 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0434 |
| March 31, 2026 | 0.0165 |
| December 31, 2025 | 0.0391 |
| September 30, 2025 | 0.0292 |
| June 30, 2025 | 0.0244 |
| March 31, 2025 | 0.0215 |
| December 31, 2024 | 0.0621 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | -1.011 |
| March 31, 2021 | -0.9703 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Enanta Pharmaceuticals, Inc. | 1.801 |
| Travere Therapeutics, Inc. | 25.16 |
| REGENXBIO, Inc. | 3.49 |
| Krystal Biotech, Inc. | 0.0065 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 11.47M |
| Total Liabilities (Quarterly) | 2.493M |
| Shareholders Equity (Quarterly) | 8.979M |
| Current Ratio | 5.738 |
| Net Debt Paydown Yield | -0.05% |